Nonalcoholic Fatty Liver Disease
While it has proven safe and effective for treating recurrent or refractory Clostridiodes difficile infections in patients with inflammatory bowel disease, fecal microbiota transplantation may also improve outcomes for patients with nonalcoholic fatty liver disease. New research hints at an answer.
Many patients with chronic hepatitis B virus (HBV) are experiencing improved outcomes thanks to the advent of antiviral therapies. However, not all patients with chronic HBV have been considered candidates for antiviral therapy. New research questions this approach.
Previous studies have shown widely varying estimates of the incidence of nonalcoholic fatty liver disease (NAFLD) in lean and nonobese individuals. In a new study, researchers sought to narrow that range and provide more clarity about the prevalence of NAFLD among lean or nonobese individuals.
Erica Monrose, MD, and Tatyana Kushner, MD, from the Icahn School of Medicine at Mount Sinai, explain the association between nonalcoholic fatty liver disease and intrahepatic cholestasis of pregnancy, diagnosing and treating NAFLD and intrahepatic cholestatis during pregnancy, and counseling your patients.